Cantor Fitzgerald Trims Illumina Inc. (ILMN) Target Price to $155.00
Illumina Inc. (NASDAQ:ILMN) had its price target reduced by stock analysts at Cantor Fitzgerald from $165.00 to $155.00 in a research note issued to investors on Tuesday. The firm presently has a “hold” rating on the life sciences company’s stock. Cantor Fitzgerald’s price target indicates a potential downside of 16.15% from the stock’s previous close.
Other equities research analysts have also issued reports about the stock. Argus boosted their price objective on shares of Illumina from $175.00 to $185.00 and gave the stock a “buy” rating in a research report on Monday, August 8th. Vetr lowered Illumina from a “strong-buy” rating to a “buy” rating and set a $167.08 price target on the stock. in a research note on Monday, July 18th. CL King started coverage on Illumina in a research note on Tuesday, June 21st. They issued a “buy” rating and a $165.00 price target on the stock. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $190.00 price objective on the stock in a research note on Friday, August 26th. Finally, Citigroup Inc. boosted their target price on Illumina from $175.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, September 12th. Two analysts have rated the stock with a sell rating, sixteen have issued a hold rating and nine have issued a buy rating to the company’s stock. Illumina currently has an average rating of “Hold” and a consensus target price of $165.12.
Shares of Illumina (NASDAQ:ILMN) opened at 184.85 on Tuesday. The firm’s 50 day moving average is $175.01 and its 200-day moving average is $156.56. Illumina has a 12 month low of $127.10 and a 12 month high of $196.47. The firm has a market capitalization of $27.10 billion, a PE ratio of 63.30 and a beta of 0.47.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/cantor-fitzgerald-trims-illumina-inc-ilmn-target-price-to-155-00.html
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.73 by $0.13. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The business had revenue of $600 million for the quarter, compared to analyst estimates of $31.91 million. During the same period in the previous year, the firm earned $0.80 EPS. The business’s revenue for the quarter was up 11.3% compared to the same quarter last year. On average, analysts expect that Illumina will post $3.53 EPS for the current fiscal year.
In other news, Director Robert S. Epstein sold 300 shares of the company’s stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $170.27, for a total transaction of $51,081.00. Following the completion of the transaction, the director now directly owns 7,224 shares of the company’s stock, valued at $1,230,030.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Charles Dadswell sold 8,632 shares of the company’s stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $155.00, for a total value of $1,337,960.00. Following the transaction, the senior vice president now directly owns 40,248 shares of the company’s stock, valued at $6,238,440. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Physicians Financial Services Inc. boosted its position in Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock valued at $103,000 after buying an additional 700 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock valued at $110,000 after buying an additional 158 shares in the last quarter. Fuller & Thaler Asset Management Inc. purchased a new position in Illumina during the second quarter valued at $112,000. Ropes Wealth Advisors LLC boosted its position in Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock valued at $121,000 after buying an additional 363 shares in the last quarter. Finally, Checchi Capital Advisers LLC boosted its position in shares of Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock valued at $134,000 after buying an additional 22 shares during the period. 95.22% of the stock is owned by institutional investors.
Illumina Company Profile
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.